Anthrax, which is caused by the spore-forming bacterium Bacillus anthracis, has become one of the major bioterrorism threats to our nation. Human vaccination in the USA with licensed protective antigen (PA)-based vaccine, Anthrax Vaccine Adsorbed (AVA), requires six immunizations followed by annual boosters. This underscores the need for development of new, improved anthrax vaccine. The long-term goal of this research is to develop an effective and easily administrated anthrax vaccine, using the B. anthracis protective antigen (PA63), the N-terminal domains of lethal factor (LFn, aminoacids 1-254) and edema factor (EFn, aminoacids 1-254) as vaccine components. Our hypothesis is that an effective vaccine should be composed of multiple relevant antigens delivered by an intranasal route in order to provide mucosal and systemic immunity against anthrax. Formulation of the anthrax vaccine into a nasal spray would allow a mass population to be immunized in a short period at a low cost. Among the currently available mucosal immunization strategies, antigen delivery with a replication-defective adenovirus is a good choice. Recombinant adenovirus and plasmid expression vectors encoding PA63, LFn and EFn will be constructed through this project. In order to evaluate the efficacy of the vaccine and provide an optimal vaccination protocol, intranasal immunization with different combinations of adenoviral vectors will be compared with immunization with plasmid expression vectors by intramuscular injection.
The specific aims of this project are: ? Specific Aim #1: To develop a recombinant adenovirus-vectored multi-component vaccine against anthrax. ? Specific Aim #2: To compare the systemic and mucosal immunity elicited by the vaccine developed in #1 through intranasal inoculation with that elicited by plasmid expression vectors through intramuscular injection. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Small Research Grants (R03)
Project #
5R03AI053598-02
Application #
6659767
Study Section
Special Emphasis Panel (ZRG1-VACC (01))
Program Officer
Zou, Lanling
Project Start
2002-09-15
Project End
2005-09-30
Budget Start
2003-09-15
Budget End
2005-09-30
Support Year
2
Fiscal Year
2003
Total Cost
$78,750
Indirect Cost
Name
University of Rochester
Department
Microbiology/Immun/Virology
Type
Schools of Dentistry
DUNS #
041294109
City
Rochester
State
NY
Country
United States
Zip Code
14627
Xu, Qingfu; Zeng, Mingtao (2008) Detoxified lethal toxin as a potential mucosal vaccine against anthrax. Clin Vaccine Immunol 15:612-6
Zeng, Mingtao; Xu, Qingfu; Pichichero, Michael E (2007) Protection against anthrax by needle-free mucosal immunization with human anthrax vaccine. Vaccine 25:3588-94
Xu, Qingfu; Hesek, Eric D; Zeng, Mingtao (2007) Transcriptional stimulation of anthrax toxin receptors by anthrax edema toxin and Bacillus anthracis Sterne spore. Microb Pathog 43:37-45
Zeng, Mingtao; Xu, Qingfu; Hesek, Eric D et al. (2006) N-fragment of edema factor as a candidate antigen for immunization against anthrax. Vaccine 24:662-70